|New Threads Only:|
|New Threads & Replies:|
Forum List » Guru News and Commentaries|
Guru News, Stock picks and commentaries
Warren Buffett Added This Health Care Stock Twice in One Month
Posted by: Victor Selva (IP Logged)
Date: December 11, 2013 04:55PM
An aging population, increasing consumer awareness and new technology will remain primary growth drivers in the coming years in the health care industry. With this promising outlook, let's take a look at Buffett´s last trade and try to explain to investors the reasons of this appealing investment opportunity.
On Dec. 10, Warren Buffett bought DaVita HealthCare Partners Inc. (DVA), a company that operates kidney dialysis centers and provides related lab services in outpatient dialysis centers.
Expanding Through Acquisitions
In 2012 DaVita acquired in a $4.4 billion purchase the company HealthCare Partners, which operates medical offices in three states. With this acquisition, it was consolidated as the largest managed health care company in the nation. But this was not the first deal; in 2011 there were others acquisitions like the one of ModernMed (a Wisconsin-based clinic group) and DSI Renal Inc. that allowed the company to increase the number of clients as well as the geographies to operate. Although it has become highly leveraged, Davita has stated that it plans to quickly de-lever back.
The story is the same in international markets. DaVita acquired Fresenius Medical Care, another leading dialysis services and products provider, and made a joint venture with Riches Healthcare (RHC). With this new entity (DaVita Taiwan) it plans to provide services to four dialysis clinics. In an important move in the Asia-Pacific region, the company acquired the dialysis operations of Malaysia's Caring Dialysis Centre Group. Other countries involved in the expansionary strategy include Saudi Arabia, China, India and Germany.
In terms of valuation, the stock sells at a trailing P/E of 23.1x, trading at a premium compared to an average of 21.1x for the industry. Analysts’ expectations imply a forward P/E of 16.56. To use another metric, its price-to-book ratio of 3.1 indicates a premium versus the industry average of 2.19 and the price-to-sales ratio of 1.2 is above the industry average of 1.1.
Earnings per share (EPS) declined by 14.1% in the most recent quarter compared to the same quarter a year ago. Also, it has demonstrated a positive trend in EPS growth over the past 10 years as shown in the next graph. We include the stock price because EPS often leads the stock price movement.
Finally, I always like to see one of the most important financial ratios applying to stockholders, the best measure of performance for a firm's management: the return on equity. The ratio has decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness.
The firm´s revenue growth has outpaced the industry average of 9.6%. I expect this trend to continue aided by expansion into different regions and strategic acquisitions. Despite having found a major weakness in the result of ROE, the firm has other highlights such as its revenue growth seen before and the increase in stock price during the past year.
For a long-term perspective, I would advise fundamental investors to consider adding DaVita their portfolios as it seems to be a high-growth company.
Hedge fund managers have also been active in the company. Hedge fund gurus like Steve Mandel, Richard Perry, Ron Barron and John Burbank have invested in it.
Disclosure: Victor Selva holds no position in any stocks mentioned.
Guru Discussed: Warren Buffett: Current Portfolio, Stock Picks
Stocks Discussed: DVA, RHC,
Disclaimers: GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.